MBMichel Billiard

Michel Billiard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michel Billiard has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Idiopathic hypersomnia, Kleine–Levin syndrome, and symptomatic hypersomnias

    by Michel Billiard, Yves Dauvilliers

    Besides obstructive sleep apnea syndrome and narcolepsy, there are a number of other causes of excessive daytime sleepiness, listed in the International Classification of Sleep Disorders, third edition, as central disorders of hypersomnolence. They include primary sleep disorders such as idiopathic hypersomnia, Kleine-Levin syndrome and a number of hypersomnias due to a medical disorder, a medication, or a substance, associated with a psychiatric disorder, or due to insufficient sleep. Idiopathic hypersomnia and Kleine–Levin syndrome have attracted much interest in recent years, and an overview of recent progresses is presented in this chapter. The symptomatic hypersomnias are less well known to sleep physicians and often neglected by specialists, either internists or psychiatrists, although they may seriously impact the quality of life of patients


  • Foreword

    by Michel Jouvet, Mehdi Tafti, Michael J. Thorpy, Paul, Mehdi, Michael, Ted Abel, Antoine Adamantidis, Karla V. Allebrandt, Simon N. Archer, et al.

    The first comprehensive book on the subject, The Genetic Basis of Sleep and Sleep Disorders covers detailed reviews of the general principles of genetics and genetic techniques in the study of sleep and sleep disorders. The book contains sections on the genetics of circadian rhythms, of normal sleep and wake states and of sleep homeostasis. There are also sections discussing the role of genetics in the understanding of insomnias, hypersomnias including narcolepsy, parasomnias and sleep-related movement disorders. The final chapter highlights the use of gene therapy in sleep disorders. Written by genetic experts and sleep specialists from around the world, the book is up to date and geared specifically to the needs of both researchers and clinicians with an interest in sleep medicine. This book will be an invaluable resource for sleep specialists, neurologists, geneticists, psychiatrists and psychologists.

  • Recurrent hypersomnia following traumatic brain injury

    by Michel Billiard, Claudio Podesta


    • 1 October 2011
      • Vol. 195  (7) , 1567

    [Hypocretin disturbance and sleep disorders].

    by Michel Billiard

    The hypothalamic hypocretin (orexin) system plays a crucial role in the regulation of sleep and wakefulness. The strongest evidence is the fact that the primary sleep disorder narcolepsy is caused by disrupted hypocretin signaling in humans as well as in various animal models. Today there is growing interest in the role of hypocretin defects in sleep disorders associated with neurodegenerative diseases. One of the most controversial issues is the functional relevance of partial hypocretin defects in these disorders.

  • Recurrent hypersomnia: A review of 339 cases

    by Michel Billiard, Isabelle Jaussent, Yves Dauvilliers, Alain Besset


  • Recurrent hypersomnias

    by Michel Billiard


  • REM Sleep Behavior Disorder and Narcolepsy

    by Michel Billiard

    REM (rapid eye movement) sleep behavior disorder (RBD) is a well known parasomnia [1]. Its first description in humans dates back to 1985, and its first description in narcoleptic patients to 1992. Although the precise pathophysiology of RBD remains unclear, it is likely, in the case of RBD associated with narcolepsy, that the altered function of hypocretin pathways projecting from the lateral hypothalamus to the ventrolateral part of the periaqueductal grey matter and the lateral pontine tegmentum has a consistent role. The percentage of narcoleptic patients complaining of clinical RBD lies somewhere between 10 and 15% of the narcoleptic population. The age of onset is younger than in the other forms of chronic RBD. Clinical features are the same as in the other forms of chronic RBD, but the frequency of the episodes is less marked. Associated features include other parasomnias, periodic limb movements in sleep (PLMs) and olfactory dysfunction. Polysomnographic tracings are remarkable for elevated submental electromyographic (EMG) tone and/or excessive phasic submental EMG twitching. Data on human leukocyte antigen (HLA) association and on cerebrospinal fluid (CSF) hypocretin/orexin levels are limited. Clinical variants include RBD induced or worsened by pharmacological agents, most of them being used to treat cataplexy, RBD in narcoleptic children and RBD in the context of symptomatic narcolepsy. Several treatments of RBD are available including clonazepam, melatonin and more recently pramipexole. However, in the absence of any pharmacological trials of these drugs on RBD in narcoleptic patients, it is difficult to provide guidance other than to recommend conventional treatments of RBD.


    • 1 June 2008
      • Vol. 4  (3) , 557-566

    Narcolepsy: current treatment options and future approaches

    by Michel Billiard

    The management of narcolepsy is presently at a turning point. Three main avenues are considered in this review: 1) Two tendencies characterize the conventional treatment of narcolepsy. Modafinil has replaced methylphenidate and amphetamine as the first-line treatment of excessive daytime sleepiness (EDS) and sleep attacks, based on randomized, double blind, placebo-controlled clinical trials of modafinil, but on no direct comparison of modafinil versus traditional stimulants. For cataplexy, sleep paralysis, and hypnagogic hallucinations, new antidepressants tend to replace tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) in spite of a lack of randomized, double blind, placebo-controlled clinical trials of these compounds; 2) The conventional treatment of narcolepsy is now challenged by sodium oxybate, the sodium salt of gammahydroxybutyrate, based on a series of randomized, double-blind, placebo-controlled clinical trials and a long-term open label study. This treatment has a fairly good efficacy and is active on all symptoms of narcolepsy. Careful titration up to an adequate level is essential both to obtain positive results and avoid adverse effects; 3) A series of new treatments are currently being tested, either in animal models or in humans, They include novel stimulant and anticataplectic drugs, endocrine therapy, and, more attractively, totally new approaches based on the present state of knowledge of the pathophysiology of narcolepsy with cataplexy, hypocretine-based therapies, and immunotherapy.


  • Traité de neuropsychologie clinique

    by Michel Billiard

    Résumé Bien que le sommeil et le coma soient physiologiquement distincts, la somnolence, définie comme un état intermédiaire entre veille et sommeil, fait également partie du continuum entre la conscience et le coma. D’où la décision justifiée des coordonnateurs de ce traité de neuropsychologie clinique de réunir en un même chapitre les états de veille et de sommeil et la conscience. Les uns et les autres constituent un vaste champ qui ne saurait être entièrement couvert dans ce chapitre. Néanmoins, les concepts principaux seront définis, les méthodes d’explorations cliniques et paracliniques passées en revue, les mécanismes résumés et les principaux troubles de la veille et du sommeil, d’une part, de la conscience, d’autre part, exposés.